A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

Thursday November 28th, 2019 | General

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, the UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment. 3P Biopharmaceuticals and In3Bio began their partnership in early 2019 with 3P Biopharmaceuticals being selected to […]

3P Biopharmaceuticals receives FDA approval

Wednesday September 18th, 2019 | General

The FDA classified 3P facilities as acceptable for the manufacture of the target molecule, and appropriate for its commercialization in the US market, once the product is authorized. 3P Biopharmaceuticals a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection […]

3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody

Thursday June 6th, 2019 | General

The arrangement covers process transfer, process development and GMP manufacture of Affibody’s candidate 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Swedish company Affibody for the process transfer, scale-up and GMP commercial manufacturing of a recombinant protein sole property of Affibody. […]